CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BBRAFV600EPredictiveSupportsSensitivity/ResponseAnaplastic Thyroid CarcinomaVemurafenibHyman et al., 2015
BBRAFV600PredictiveSupportsSensitivity/ResponseColorectal CancerCetuximab,Alpelisib,Encorafenibvan Geel et al., 2017
CVHLR82_V84del (c.244_252del)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLL188Q (c.563T>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLA56_P59del (c.166_178del)PredisposingSupportsUncertain SignificanceRenal Cell CarcinomaWhaley et al., 1994
CACVR1G328EDiagnosticSupportsPositiveDiffuse Midline Glioma, H3 K27M-mutantTaylor et al., 2014
Cv::NRG1FusionPredictiveDoes Not SupportSensitivity/ResponseMucinous AdenocarcinomaAfatinibDrilon et al., 2018
CSTRN::NTRK2FusionPredictiveSupportsSensitivity/ResponseSarcomaLarotrectinibLaetsch et al., 2018
CLMNA::NTRK1FusionPredictiveSupportsSensitivity/ResponseSarcomaLarotrectinibLaetsch et al., 2018
CPDE4DIP::NTRK1FusionPredictiveSupportsSensitivity/ResponseSarcomaLarotrectinibLaetsch et al., 2018
CSQSTM1::NTRK1FusionPredictiveSupportsSensitivity/ResponseCongenital FibrosarcomaLarotrectinibLaetsch et al., 2018
CVHLL128R (c.383T>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseRuiz-Llorente et al., 2004
CVHLV130L (c.388G>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseRuiz-Llorente et al., 2004
CVHLR161* (c.481C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseRuiz-Llorente et al., 2004
CVHLL184P (c.551T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseRuiz-Llorente et al., 2004
CVHLF76del (c.227_229del)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseHes et al., 2007
CVHLW88fs (c.261dup)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseHes et al., 2007
BBRAFV600EPredictiveDoes Not SupportSensitivity/ResponseColorectal AdenocarcinomaPanitumumab,TrametinibCorcoran et al., 2018
CERBB2OverexpressionPredictiveSupportsSensitivity/ResponseSalivary Gland CancerZoledronic Acid,Capecitabine,TrastuzumabSharon et al., 2010
DERBB2T798IPredictiveDoes Not SupportSensitivity/ResponseBreast CancerOsimertinibHanker et al., 2017
BEGFRExon 19 DeletionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaGefitinibUrata et al., 2016
BPIK3CAMutationPrognosticSupportsBetter OutcomeBreast CancerPérez-Tenorio et al., 2007
BPIK3CAMutationPredictiveDoes Not SupportSensitivity/ResponseEstrogen-receptor Positive Breast CancerTamoxifenPérez-Tenorio et al., 2007
DBCR::ABL1Fusion AND ABL1 T315APredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBurgess et al., 2005
BPIK3CAE542K OR PIK3CA E545K OR PIK3CA H1047RPredictiveDoes Not SupportResistanceBreast CancerFEC Regimen,FAC RegimenLiedtke et al., 2008
CBCR::ABL1Fusion AND ABL1 Y253HPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib Mesylate,NilotinibHughes et al., 2009
DPIK3CAH1047RPredictiveSupportsResistanceHer2-receptor Positive Breast CancerLapatinibEichhorn et al., 2008
DPIK3CAH1047RPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabEichhorn et al., 2008
DPIK3CAE545KPredictiveSupportsResistanceHer2-receptor Positive Breast CancerLapatinibEichhorn et al., 2008
DBCR::ABL1Fusion AND ABL1 F317VPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBurgess et al., 2005
DPIK3CAE545KPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabEichhorn et al., 2008
DBCR::ABL1Fusion AND ABL1 L248RPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib Mesylate,DasatinibBurgess et al., 2005
DPIK3CAE545KPredictiveSupportsResistanceHer2-receptor Positive Breast CancerLapatinib,TrastuzumabEichhorn et al., 2008
DPIK3CAE545KPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerDactolisibEichhorn et al., 2008
DBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinib,Imatinib MesylateBurgess et al., 2005
DBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBurgess et al., 2005
DBCR::ABL1Fusion AND ABL1 V299LPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibBurgess et al., 2005
CVHLR161* (c.481C>T)PredisposingN/AVon Hippel-Lindau DiseaseMathó et al., 2016
CVHLR167Q (c.500G>A)PredisposingN/AVon Hippel-Lindau DiseaseTaylor et al., 2018
CBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinib,Imatinib MesylateHughes et al., 2009
CBCR::ABL1Fusion AND ABL1 F359CPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib Mesylate,NilotinibHughes et al., 2009
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib Mesylate,DasatinibBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinib,DasatinibBradeen et al., 2006
DAKT1OverexpressionPredictiveDoes Not SupportResistanceMelanomaVemurafenibShi et al., 2014
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib Mesylate,Dasatinib,NilotinibBradeen et al., 2006
CVHL3p26.3-25.3 11Mb delPredisposingN/AVon Hippel-Lindau DiseaseSuzuki-Muromoto et al., 2016
CVHLExon 3 DeletionPredisposingSupportsPredispositionVon Hippel-Lindau DiseaseValero et al., 2016
BKRASG12/G13PrognosticDoes Not SupportPoor OutcomeColorectal CancerSouglakos et al., 2009
BKRASG12/G13PredictiveDoes Not SupportResistanceColorectal CancerOxaliplatinSouglakos et al., 2009
BKRASG12/G13PredictiveDoes Not SupportResistanceColorectal CancerIrinotecanSouglakos et al., 2009
Page 51 of 96
PreviousNext